The bill amends the existing law on "Collaborative Pharmacy Practice" to expand the scope of collaborative practice agreements by allowing licensed pharmacists to collaborate not only with physicians but also with other healthcare providers. Key definitions are updated, including the replacement of "physicians" with "providers" in various contexts. A "collaborative practice agreement" is defined as a written and signed agreement that outlines the roles and responsibilities of the involved parties in drug therapy management. The bill mandates that these agreements be submitted to the board of pharmacy for record-keeping purposes, although no approval process is required before the parties can begin acting under the agreement.

Additionally, the bill removes the definition of the "collaborative practice committee," which previously consisted of appointed individuals from pharmacy and medical boards, thereby streamlining the regulatory framework. It clarifies that collaborative practice agreements must be made in the best interest of public health, follow clinical guidelines and standards of care, and be agreed upon with the collaborating provider. The agreements must be reviewed and signed by the parties annually and refiled with the board if substantive changes impacting patient care are made. The bill is set to take effect on July 1, 2025.